Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate
Combination drug
From Wikipedia, the free encyclopedia
Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women.[1] It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection.[1] The medication was developed by 1957.[1] It is no longer available.[2][3]
Trade namesTriormon Depositum
| Combination of | |
|---|---|
| Estradiol dibutyrate | Estrogen |
| Hydroxyprogesterone heptanoate | Progestogen |
| Testosterone cyclohexylpropionate | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Triormon Depositum |
| Other names | EDBu/OHPH/TCa |
| Routes of administration | Intramuscular injection |
